Telehealth company Hims & Hers Health (NYSE:HIMS) announced in Q4 CY2024, with sales up 95.1% year on year to $481.1 million.

Hims shares have roughly doubled since the start of the year, despite the FDA’s announcement last week that Novo Nordisk’s ...

Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...

Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December ...

智通财经APP获悉，周三，Hims & Hers Health(HIMS.US)股价拉涨，截至发稿，该股涨超15%，报67.4美元。消息面上，该公司已成功收购一家家庭实验室检测 ...

在美国平价医疗保健公司Hims & Hers Health(HIMS.US)下周公布2024 年第四季度业绩之前，摩根士丹利周二将其评级从“增持”下调至“持平”，理由是该公司股票近期的强劲上涨。 自去年5月以来，总部位于加州旧金山的HIMS股价已攀升超过200%，当时该公司以大幅折扣推出了诺和诺德(NVO.US)广受欢迎的减肥疗法司美格鲁肽的复方版本。 摩根士丹利分析师Craig Hettenba ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

在最近的金融市场中，美股的AI医疗股表现出色，其中Firefly Neuroscience的股价猛增超过20%，而Hims & Hers Health和Tempus AI分别上涨了14%和7%。这种强劲的市场反应不仅吸引了投资者的注意，更是引发了对人工智能在医疗领域应用前景的广泛讨论。本文将深入分析这些AI医疗公司的涨势背后的原因，并探讨AI技术如何重新定义医疗行业的未来。 AI医疗概念的崛起 随 ...

Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...

Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...